Modulation of neuronal nkcc1 as a therapeutic strategy for spasticity and related disorders
US-2024416127-A1 · Dec 19, 2024 · US
Drug for retinal degenerative disease associated with photoreceptor degeneration
US11931327B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11931327-B2 |
| Application number | US-201816628232-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 3, 2018 |
| Priority date | Jul 4, 2017 |
| Publication date | Mar 19, 2024 |
| Grant date | Mar 19, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating retinitis pigmentosa, comprising administering tamibarotene or tamibarotene ethyl ester, or a salt thereof. 2. The method according to claim 1 , wherein the method comprises administering tamibarotene. 3. The method according to claim 1 , wherein tamibarotene or tamibarotene ethyl ester, or the salt thereof, is topically administered to the eye.
Assignees
Inventors
Classifications
having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} · CPC title
- A61K31/196Primary
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
Genetically modified vertebrates, e.g. transgenic · CPC title
Eye, e.g. artificial tears · CPC title
having an amino or nitro group · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11931327B2 cover?
- An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid recept…
- Who is the assignee on this patent?
- Daiichi Sankyo Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/196. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).